Abstract
Introduction: High-risk human papillomavirus (HR HPV) is found to be responsible for 4.5% of cancer in general, primarily cervical cancer. We aim here to highlight the prevalence and genotypes of HR HPV and correlate its association with Pap tests’ results, which are still not well known in the Eastern Province of Saudi Arabia. Methods: Over 7 years (2013–2019), the results of 164 Saudi women coinvestigated for HR HPV along with Pap tests were collected from the archive of King Fahd University Hospital. Only women who had atypical squamous cells of undetermined significance (ASCUS) on the Pap test and those at elevated risk of infection were cotested for HR HPV; otherwise, the Pap test was the only screening modality for cervical cancer. Data were organized and statistically analyzed using IBM SPSS v26. Results: Out of 164 Saudi women, 14.5% (n = 24/164) showed positive results for HR HPV (8 patients had HPV16 and 2 had both HPV16 and HPV18/45, while the remaining 14 had other HR HPV); among them, 41.5% (n = 10/24) had an abnormal Pap test (5 ASCUS and 5 LSIL), while 58.5% (n = 14/24) had a negative Pap test. On the other hand, 21% (n = 35/164) of patients, in the study, had an abnormal Pap test (24 ASCUS, 8 low-grade squamous intraepithelial lesion [LSIL], and 3 atypical glandular cell [AGC]). In 80% (n = 19/24) of ASCUS cases, HR HPV was not detected; however, 20% (n = 5/24) were positive for other HR HPV. Concerning LSIL cases, 62.5% (n = 5/8) were positive for HR HPV (1 case showed HPV16 and HPV18/45, 2 cases showed HPV16, and 2 cases showed other HR HPV), while in the remaining 37.5% (n = 3/8) LSIL cases, HR HPV was negative; similarly, all AGC cases were negative for HR HPV. Statistical analysis showed a significant correlation between HPV status and Pap test findings (p value <0.001). Discussion/Conclusion: HR HPV frequency and genotype distribution, in this study, might reflect a different regional infection pattern. The high association of HR HPV with negative cytology emphasizes the need to add the HR HPV test to screening modalities of cervix cancer.
References
1.
Serrano
B
, Brotons
M
, Bosch
FX
, Bruni
L
. Epidemiology and burden of HPV-related disease
. Best Pract Res Clin Obstet Gynaecol
. 2018 Feb
;47
:14
–26
. 2.
de Martel
C
, Plummer
M
, Vignat
J
, Franceschi
S
. Worldwide burden of cancer attributable to HPV by site, country and HPV type
. Int J Cancer
. 2017 Aug 15
;141
(4
):664
–70
. 3.
Syrjänen
S
, Syrjänen
K
. HPV in head and neck carcinomas: different HPV profiles in oropharyngeal carcinomas: why?
Acta Cytol
. 2019
;63
(2
):124
–42
. 4.
Crow
JM
. HPV: the global burden
. Nature
. 2012 Aug 30
;488
(7413
):S2
–3
. 5.
de Sanjosé
S
, Brotons
M
, Pavón
MA
. The natural history of human papillomavirus infection
. Best Pract Res Clin Obstet Gynaecol
. 2018 Feb
;47
:2
–13
. 6.
Forman
D
, de Martel
C
, Lacey
CJ
, Soerjomataram
I
, Lortet-Tieulent
J
, Bruni
L
, et al Global burden of human papillomavirus and related diseases
. Vaccine
. 2012 Nov 20
;30
(Suppl 5
):F12
–23
. 7.
Hoffman
SR
, Le
T
, Lockhart
A
, Sanusi
A
, Dal Santo
L
, Davis
M
, et al Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): a systematic review
. Int J Cancer
. 2017 Jul 1
;141
(1
):8
–23
. 8.
Syrjanen
K
. Persistent high-risk human papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation (non-HPV 16/18) prophylactic HPV vaccines
. Eur J Gynaecol Oncol
. 2011
;32
(1
):17
–33
.9.
Moscicki
AB
, Ma
Y
, Farhat
S
, Darragh
TM
, Pawlita
M
, Galloway
DA
, et al Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16
. J Infect Dis
. 2013 Aug 1
;208
(3
):403
–12
. 10.
Zhao
X
, Zhao
S
, Hu
S
, Zhao
K
, Zhang
Q
, Zhang
X
, et al Role of human papillomavirus DNA load in predicting the long-term risk of cervical cancer: a 15-year prospective cohort study in China
. J Infect Dis
. 2019 Jan 7
;219
(2
):215
–22
. 11.
Markowitz
LE
, Dunne
EF
, Saraiya
M
, Chesson
HW
, Curtis
CR
, Gee
J
, et al Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)
. MMWR Recomm Rep
. 2014 Aug 29
;63
(RR-05
):1
–30
.12.
de Oliveira
CM
, Fregnani
JHTG
, Villa
LL
. HPV vaccine: updates and highlights
. Acta Cytol
. 2019
;63
(2
):159
–68
.13.
Leite
KRM
, Pimenta
R
, Canavez
J
, Canavez
F
, de Souza
FR
, Vara
L
, et al HPV genotype prevalence and success of vaccination to prevent cervical cancer
. Acta Cytol
. 2020 Apr 1
:1
–5
. 14.
Alsbeih
G
. HPV infection in cervical and other cancers in Saudi Arabia: implication for prevention and vaccination
. Front Oncol
. 2014
;4
:65
. 15.
Petrosky
E
, Bocchini
JA
Jr, Hariri
S
, Chesson
H
, Curtis
CR
, Saraiya
M
, et al Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices
. MMWR Morb Mortal Wkly Rep
. 2015 Mar 27
;64
(11
):300
–4
.16.
Committee on Practice Bulletins—Gynecology
. Practice bulletin no. 168 summary: cervical cancer screening and prevention
. Obstet Gynecol
. 2016 Oct
;128
(4
):923
–5
. 17.
US Preventive Services Task Force
; Curry
SJ
, Krist
AH
, Owens
DK
, Barry
MJ
, Caughey
AB
, et al Screening for cervical cancer: US preventive services task force recommendation statement
. JAMA
. 2018 Aug 21
;320
(7
):674
–86
.18.
Li
T
, Li
Y
, Yang
GX
, Shi
P
, Sun
XY
, Yang
Y
, et al Diagnostic value of combination of HPV testing and cytology as compared to isolated cytology in screening cervical cancer: a meta-analysis
. J Cancer Res Ther
. 2016 Jan-Mar
;12
(1
):283
–9
. 19.
Katki
HA
, Schiffman
M
, Castle
PE
, Fetterman
B
, Poitras
NE
, Lorey
T
, et al Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results
. J Low Genit Tract Dis
. 2013 Apr
;17
(5 Suppl 1
):S43
–9
. 20.
Alanen
KW
, Elit
LM
, Molinaro
PA
, McLachlin
CM
. Assessment of cytologic follow-up as the recommended management for patients with atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions
. Cancer
. 1998 Feb 25
;84
(1
):5
–10
. 21.
Oliveira
GG
, Oliveira
JMDSC
, Eleutério
RMN
, Barbosa
RCC
, Almeida
PRC
, Eleutério
J
Jr. Atypical squamous cells: cytopathological findings and correlation with HPV genotype and histopathology
. Acta Cytol
. 2018
;62
(5–6
):386
–92
. 22.
Jordan
J
, Arbyn
M
, Martin-Hirsch
P
, Schenck
U
, Baldauf
JJ
, Da Silva
D
, et al European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1
. Cytopathology
. 2008 Dec
;19
(6
):342
–54
. 23.
Arbyn
M
, Ronco
G
, Anttila
A
, Meijer
CJ
, Poljak
M
, Ogilvie
G
, et al Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer
. Vaccine
. 2012 Nov 20
;30
(Suppl 5
):F88
–99
. 24.
Ronco
G
, Dillner
J
, Elfström
KM
, Tunesi
S
, Snijders
PJ
, Arbyn
M
, et al Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials
. Lancet
. 2014 Feb 8
;383
(9916
):524
–32
. 25.
Patnick
J
. Review of recommendations on cervical cancer screening in the European Union
. Minerva Ginecol
. 2003 Aug
;55
(4
):293
–5
.26.
Madom
LM
, Boardman
LA
. HPV testing and cervical cancer screening: recommendations and practice patterns
. Med Health R I
. 2005 Oct
;88
(10
):362
–3
.27.
Kitchener
HC
, Gilham
C
, Sargent
A
, Bailey
A
, Albrow
R
, Roberts
C
, et al A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial
. Eur J Cancer
. 2011 Apr
;47
(6
):864
–71
. 28.
Bergeron
C
, von Knebel Doeberitz
M
. The role of cytology in the 21st century: the integration of cells and molecules
. Acta Cytol
. 2016
;60
(6
):540
–2
. 29.
Anfinan
NM
. Physician’s knowledge and opinions on human papillomavirus vaccination: a cross-sectional study, Saudi Arabia
. BMC Health Serv Res
. 2019 Dec
;19
(1
):963
. 30.
Mousa
M
, Al-Amri
SS
, Degnah
AA
, Tolah
AM
, Abduljabbar
HH
, Oraif
AM
, et al Prevalence of human papillomavirus in Jeddah, Saudi Arabia
. Ann Saudi Med
. 2019 Nov–Dec
;39
(6
):403
–9
. 31.
Nayar
R
, Wilbur
DC
. The Bethesda system for reporting cervical cytology: definitions, criteria, and explanatory notes
. 3rd ed. Cham
: Springer
; 2015
.32.
Karimi-Zarchi
M
, Tabatabaie
A
, Dehghani-Firoozabadi
A
, Shamsi
F
, Baghianimoghaddam
M
, Dargahi
M
, et al The most common type of HPV in women with atypical squamous cell of undetermined significance (ASCUS) in Pap smear in Iran-Yazd
. Int J Biomed Sci
. 2015 Dec
;11
(4
):173
–5
.33.
Clifford
GM
, Smith
JS
, Plummer
M
, Muñoz
N
, Franceschi
S
. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis
. Br J Cancer
. 2003 Jan
;88
(1
):63
–73
. 34.
Beyazit
F
, Sılan
F
, Gencer
M
, Aydin
B
, Paksoy
B
, Unsal
MA
, et al The prevelance of human papillomavirus (HPV) genotypes detected by PCR in women with normal and abnormal cervico-vaginal cytology
. Ginekol Pol
. 2018
;89
(2
):62
–7
. 35.
Gupta
S
, Sodhani
P
. Reducing “atypical squamous cells” overdiagnosis on cervicovaginal smears by diligent cytology screening
. Diagn Cytopathol
. 2012 Sep
;40
(9
):764
–9
. 36.
Zheng
B
, Yang
H
, Li
Z
, Wei
G
, You
J
, Liang
X
, et al HPV test results and histological follow-up results of patients with LSIL cervical cytology from the largest CAP-certified laboratory in China
. J Cancer
. 2017
;8
(13
):2436
–41
. 37.
Barron
S
, Austin
RM
, Li
Z
, Zhao
C
. Follow-up outcomes in a large cohort of patients with HPV-negative LSIL cervical screening test results
. Am J Clin Pathol
. 2015 Apr
;143
(4
):485
–91
. 38.
Patadji
S
, Li
Z
, Pradhan
D
, Zhao
C
. Significance of high-risk HPV detection in women with atypical glandular cells on Pap testing: analysis of 1857 cases from an academic institution
. Cancer
. 2017 Mar
;125
(3
):205
–11
. 39.
González-Bosquet
E
, Fernandez
S
, Sabra
S
, Lailla
JM
. Negative HPV testing among patients with biopsy-proven cervical intraepithelial neoplasia grade 2/3 or cervical cancer
. Int J Gynaecol Obstet
. 2017 Feb
;136
(2
):229
–31
. 40.
Al-Awadhi
R
, Chehadeh
W
, Kapila
K
. Prevalence of human papillomavirus among women with normal cervical cytology in Kuwait
. J Med Virol
. 2011 Mar
;83
(3
):453
–60
. 41.
de Sanjosé
S
, Diaz
M
, Castellsagué
X
, Clifford
G
, Bruni
L
, Muñoz
N
, et al Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis
. Lancet Infect Dis
. 2007 Jul
;7
(7
):453
–9
. 42.
Rizzo
AE
, Feldman
S
. Update on primary HPV screening for cervical cancer prevention
. Curr Probl Cancer
. 2018 Sep
;42
(5
):507
–20
. 43.
Yousif
HM
, Albasri
AM
, Alshanqite
MM
, Missawi
HM
. Histopathological patterns and characteristics of abnormal cervical smear in Madinah region of Saudi Arabia
. Asian Pac J Cancer Prev
. 2019 May 25
;20
(5
):1303
–7
. 44.
Xu
HH
, Lin
A
, Chen
YH
, Dong
SS
, Shi
WW
, Yu
JZ
, et al Prevalence characteristics of cervical human papillomavirus (HPV) genotypes in the Taizhou area, China: a cross-sectional study of 37 967 women from the general population
. BMJ Open
. 2017 Jun 9
;7
(6
):e014135
. 45.
Huijsmans
CJ
, Geurts-Giele
WR
, Leeijen
C
, Hazenberg
HL
, van Beek
J
, de Wild
C
, et al HPV prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows
. BMC Cancer
. 2016 Nov 28
;16
(1
):922
. 46.
Bruni
L
, Diaz
M
, Castellsagué
X
, Ferrer
E
, Bosch
FX
, de Sanjosé
S
. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings
. J Infect Dis
. 2010 Dec 15
;202
(12
):1789
–99
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
